Product Description: Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research[1].
Applications: Neuroscience-Neurodegeneration
Formula: N/A
References: [1]S Zampar, et al. N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease. Neuropathol Appl Neurobiol. 2020 Dec;46(7):673-685.
CAS Number: 1095207-05-8
Molecular Weight: N/A
Compound Purity: 97.27
Research Area: Neurological Disease
Solubility: 10 mM in DMSO
Target: Amyloid-β